DMAC News and Press, DiaMedica Therapeutics Inc. From 08/12/25

2025-08-12 16:19:53 ET More on DiaMedica Therapeutics DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer DiaMedica Therapeutics raises $30 million in private placement Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical e...

Reeds Inc. (REED) is expected to report $-0.04 for Q2 2025 Jerash Holdings (US) Inc. (JRSH) is expected to report for Q1 2026 Churchill Capital Corp IX (CCIX) is expected to report for quarter end 2025-06-30 Verde Clean Fuels Inc. (VGAS) is expected to report for Q2 2025 Mobile In...

2025-08-06 08:48:48 ET More on DiaMedica Therapeutics DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript DiaMedica Therapeutics raises $30 million in private placement DiaMedica gains on positive mid-stage trial data for lead drug in preeclampsia ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the appointment of Julie Krop, MD, as Chief Medical Officer (CMO), effective immediat...

Sera Prognostics Inc. (SERA) is expected to report $-0.21 for Q2 2025 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.51 for Q2 2025 Context Therapeutics Inc. (CNTX) is expected to report $-0.06 for Q2 2025 Genco Shipping & Trading ...

DiaMedica Therapeutics Inc. (DMAC) is expected to report $-0.18 for Q2 2025

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its second quarter 2025 financial results will be released after the markets close on Tuesday, August 12 ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the closing of its previously announced $30.1 million private placement of common sha...

2025-07-22 14:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-07-21 08:27:48 ET More on DiaMedica Therapeutics DiaMedica gains on positive mid-stage trial data for lead drug in preeclampsia DiaMedica Therapeutics to be included in the Russell 2000 and 3000 indexes Seeking Alpha’s Quant Rating on DiaMedica Therapeuti...